Anzeige
Mehr »
Login
Montag, 24.02.2025 Börsentäglich über 12.000 News von 688 internationalen Medien
851 % Rendite in 30 Tagen: Die KI-Aktie, die seit der Integration von Deepseek R1 Wellen schlägt!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40P0G | ISIN: US76090R3093 | Ticker-Symbol: 24O
NASDAQ
21.02.25
21:30 Uhr
1,150 US-Dollar
-0,080
-6,50 %
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
RESHAPE LIFESCIENCES INC Chart 1 Jahr
5-Tage-Chart
RESHAPE LIFESCIENCES INC 5-Tage-Chart

Aktuelle News zur RESHAPE LIFESCIENCES Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoReShape Lifesciences Inc. - 8-K, Current Report-
MiPre-market Movers: Sintx Technologies, Cycurion, OSR Holdings, ReShape Lifesciences, NewGenIvf Group394BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 07.35 A.M. ET).In the Green Sintx Technologies, Inc. (SINT) is up over 87%...
► Artikel lesen
17.02.ReShape Lifesciences prices $6M public offering3
RESHAPE LIFESCIENCES Aktie jetzt für 0€ handeln
16.02.ReShape Lifesciences Inc: ReShape Lifesciences Announces Pricing of Upsized $6.0 Million Public Offering5
13.02.RSLS-Aktie erreicht 52-Wochen-Tief bei 2,57 US-Dollar2
13.02.ReShape Lifesciences Inc. - S-1/A, General form for registration of securities-
06.02.ReShape Lifesciences Inc. - S-1/A, General form for registration of securities1
03.02.ReShape Lifesciences sichert sich wichtiges Patent für Diabetes-Behandlung2
03.02.ReShape Lifesciences receives international patent in Israel for its proprietary diabetes neuromodulation technology; shares rise4
03.02.ReShape Lifesciences Inc: ReShape Lifesciences Granted Key International Patent in Israel for Its Proprietary Diabetes Neuromodulation Technology62IRVINE, Calif., Feb. 03, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that the Company...
► Artikel lesen
28.01.RSLS-Aktie erreicht 52-Wochen-Tief bei 4,07 US-Dollar1
21.01.ReShape Lifesciences Inc. - 8-K, Current Report-
21.01.ReShape Lifesciences Inc. - S-1, General form for registration of securities-
15.01.ReShape Lifesciences Inc. - S-4/A, Registration of securities, business combinations-
15.01.ReShape Lifesciences Inc. - S-1/A, General form for registration of securities-
13.01.ReShape Lifesciences Inc: ReShape Lifesciences Provides Update on Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement With Biorad Medisys92IRVINE, Calif. and CAMBRIDGE, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, and Vyome...
► Artikel lesen
27.12.24ReShape Lifesciences Inc. - 8-K, Current Report-
20.12.24ReShape Lifesciences files to sell up to 2.11M shares for holder2
20.12.24ReShape Lifesciences Inc. - S-1, General form for registration of securities-
11.12.24RSLS-Aktie erreicht 52-Wochen-Tief bei 4,48 US-Dollar2
Seite:  Weiter >>
36 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1